The Deal Register
Database › Debt financing › Synakis Announces Close of Oversubscribed Pre-Seed Round

Debt financing

Synakis Announces Close of Oversubscribed Pre-Seed Round

Lane
Debt financing
Announced
21 May 2026
Province
Ontario
Industry
Unclassified
Status
Announced
What the filing says
Synakis Corp., a Toronto-based biotechnology company developing ocular therapies for retinal disease and glaucoma, announced today the close of an oversubscribed CAD $2.6 million pre-seed financing round to advance SNK-125, its vitreous replacement therapy for retinal detachment.
Source

The terms are in the subscriber edition

This transaction carries the consideration.

Subscribe

Compiled from public filings, court documents, exchange bulletins and issuer releases. Figures are as disclosed and are not independently verified.

Not financial, investment, legal or tax advice, and not an offer to buy or sell any security. Verify everything before you transact.

The Deal Register · Archive · Subscribe